Findings in allergies reported from H.B. Li and co-researchers

   "Expression of CLC-3 was detected by immunohistochemistry and by reverse transcription-polymerase chain reaction before and at 4 weeks after treatment with the topical corticosteroid mometasone furoate. Strong CLC-3 expression was detected in epithelium and in submucosal glands. An increased presence of CLC-3 was demonstrated in nasal mucosa compared with that in normal nasal tissue. A statistically significant difference in CLC-3 gene expression level was found in nasal tissues before vs at 4 weeks after treatment with mometasone. CLC-3 may have a role in modulating the pathogenesis of AR," wrote H.B. Li and colleagues.

   The researchers concluded: "Decreased expression of CLC-3 may be the mechanism of action of corticosteroid treatment in controlling AR."

   Li and colleagues published their study in Archives of Otolaryngology - Head & Neck Surgery (Expression of chloride channel protein CLC-3 in patients with allergic rhinitis - Effect of topical corticosteroid treatment. Archives of Otolaryngology - Head & Neck Surgery, 2008;134(3):301-305).

   For additional information, contact G. Xu, Sun Yat Sen UniversityOtorhinolaryngology Hospital, Affiliated Hospital 1, Guangzhou 510080, People's Republic of China.

   Publisher contact information for the journal Archives of Otolaryngology - Head & Neck Surgery is: American Medical Association, 515 N State St., Chicago, IL 60610-0946, USA.

   Keywords: People's Republic of China, Guangzhou, Allergic Rhinitis, Allergies, Allergy Medicine, Biotechnology, Corticosteroid, Diagnosis, Diagnostics, Enzyme Research, Gene Therapy, Laryngology, Otolaryngology, Polymerase, Surgery.

   This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2008, Biotech Business Week via NewsRx.com.

Return to Gene Therapy Alert Section